ATE462803T1 - Kit und verfahren zum nachweis von urothelkarzinom - Google Patents

Kit und verfahren zum nachweis von urothelkarzinom

Info

Publication number
ATE462803T1
ATE462803T1 AT06797321T AT06797321T ATE462803T1 AT E462803 T1 ATE462803 T1 AT E462803T1 AT 06797321 T AT06797321 T AT 06797321T AT 06797321 T AT06797321 T AT 06797321T AT E462803 T1 ATE462803 T1 AT E462803T1
Authority
AT
Austria
Prior art keywords
kit
detecting
protein
urothelic
carcinoma
Prior art date
Application number
AT06797321T
Other languages
English (en)
Inventor
Hideo Akiyama
Yoshinori Tanaka
Satoko Kozono
Hitoshi Nobumasa
Osamu Ogawa
Takeshi Takahashi
Original Assignee
Toray Industries
Univ Kyoto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries, Univ Kyoto filed Critical Toray Industries
Application granted granted Critical
Publication of ATE462803T1 publication Critical patent/ATE462803T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT06797321T 2005-09-02 2006-09-01 Kit und verfahren zum nachweis von urothelkarzinom ATE462803T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005255370 2005-09-02
JP2006017379 2006-09-01

Publications (1)

Publication Number Publication Date
ATE462803T1 true ATE462803T1 (de) 2010-04-15

Family

ID=37808979

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06797321T ATE462803T1 (de) 2005-09-02 2006-09-01 Kit und verfahren zum nachweis von urothelkarzinom

Country Status (10)

Country Link
US (1) US7910316B2 (de)
EP (1) EP1930445B1 (de)
JP (1) JP5078015B2 (de)
KR (1) KR101393144B1 (de)
CN (1) CN101297046B (de)
AT (1) ATE462803T1 (de)
CA (1) CA2621060A1 (de)
DE (1) DE602006013333D1 (de)
ES (1) ES2343276T3 (de)
WO (1) WO2007026895A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9499864B2 (en) 2003-11-03 2016-11-22 Aab Patent Holding Aps Expression of FABP4 and other genes associated with bladder cancer progression
EP2166358A1 (de) * 2008-09-17 2010-03-24 Fundacio Institut de Recerca de l'Hospital Universitari Vall d'Hebron Differentialdiagnostisches Biomarker von einen Schlaganfall imitierenden Bedingungen und Verfahren zur Verwendung dieser
KR101682257B1 (ko) 2008-10-31 2016-12-05 도레이 카부시키가이샤 인간 ｃｘｃｌ１ 단백질의 면역학적 측정 방법
CN104034901A (zh) * 2008-11-22 2014-09-10 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
CA2772068C (en) * 2009-08-25 2017-03-21 Cytotech Labs, Llc Methods for treatment of a sarcoma using an epimetabolic shifter (coenzyme q10)
WO2011109810A2 (en) 2010-03-05 2011-09-09 H. Lee Moffitt Cancer Center And Research Institute, Inc. Methods of predicting high grade gliomas using senescence associated genes
NZ589251A (en) * 2010-11-12 2014-07-25 Pacific Edge Ltd Novel marker for detection of bladder cancer
EP2798079B1 (de) 2011-12-30 2016-09-07 Abbott Molecular Inc. Materialien und verfahren zur diagnose von blasenkrebs und zur überwachung des erneuten auftretens davon
EP2910948B1 (de) * 2012-10-17 2018-07-11 Public University Corporation Nara Medical University Neuartige krebsmarker und verwendung davon
SG10201804276UA (en) * 2013-11-21 2018-06-28 Pacific Edge Ltd Triaging of patients having asymptomatic hematuria using genotypic and phenotypic biomarkers
CN105505941A (zh) * 2016-01-21 2016-04-20 中国人民解放军第四军医大学 Cxcl1的适配体在制备检测上尿路上皮癌试剂中的应用
JPWO2020071489A1 (ja) * 2018-10-04 2021-09-24 国立大学法人大阪大学 尿路上皮がんを検査する方法
JP2022517865A (ja) * 2019-01-28 2022-03-10 ジェイ ロッサ― チャールズ Ｃｘｃｌ１機能に関与する疾患の治療のための組成物および方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07309895A (ja) 1994-05-20 1995-11-28 Idemitsu Kosan Co Ltd 新規タンパク質、その検出方法及び診断薬
JPH1054830A (ja) 1996-08-12 1998-02-24 Omomo Souuemon テストストリップの製造システム
JP2000131321A (ja) 1998-10-28 2000-05-12 Igaku Seibutsugaku Kenkyusho:Kk 膀胱癌患者の予後診断薬
US20050123938A1 (en) 1999-01-06 2005-06-09 Chondrogene Limited Method for the detection of osteoarthritis related gene transcripts in blood
JP2002238599A (ja) 2001-02-21 2002-08-27 Yoshihiko Funae 膀胱癌の診断方法および診断キット
US20030190602A1 (en) * 2001-03-12 2003-10-09 Monogen, Inc. Cell-based detection and differentiation of disease states
JP4109032B2 (ja) 2002-07-29 2008-06-25 株式会社福山臨床検査センター 膀胱癌の検査判定方法
JP4207187B2 (ja) 2002-09-30 2009-01-14 財團法人奇美醫院 膀胱癌に対する分子マーカーとしてのｈｕｒｐ遺伝子
US20060188889A1 (en) * 2003-11-04 2006-08-24 Christopher Burgess Use of differentially expressed nucleic acid sequences as biomarkers for cancer
JP2004337120A (ja) 2003-05-19 2004-12-02 Chang Gung Univ 膀胱癌再発検査方法
CA2528162A1 (en) * 2003-06-04 2004-12-16 The Government Of The United States As Represented By The Secretary Of T He Department Of Health And Human Services, Centers For Disease Control Pni microarray and uses
JP2005255370A (ja) 2004-03-15 2005-09-22 Mitsubishi Electric Corp エレベーターの制御装置

Also Published As

Publication number Publication date
CN101297046A (zh) 2008-10-29
ES2343276T3 (es) 2010-07-27
US20100009347A1 (en) 2010-01-14
DE602006013333D1 (de) 2010-05-12
EP1930445A4 (de) 2008-12-10
US7910316B2 (en) 2011-03-22
EP1930445A1 (de) 2008-06-11
CN101297046B (zh) 2013-01-02
WO2007026895A1 (ja) 2007-03-08
KR20080046693A (ko) 2008-05-27
EP1930445B1 (de) 2010-03-31
JPWO2007026895A1 (ja) 2009-03-12
KR101393144B1 (ko) 2014-05-08
CA2621060A1 (en) 2007-03-08
JP5078015B2 (ja) 2012-11-21

Similar Documents

Publication Publication Date Title
NO339224B1 (no) Bedrede immunprøvemetoder
DE50115173D1 (de) Verfahren zur spezifischen Detektion von Tumorzellen und ihren Vorstufen in Gebärmutterhalsabstrichen durch simultane Messung von mindestens 2 verschiedenen molekularen Markern
ATE549625T1 (de) Verfahren und zusammensetzungen zum nachweis einer zervixerkrankung
ATE538386T1 (de) Nachweis von krebs anhand von erhöhten bcl-2- konzentrationen
ATE471512T1 (de) Verwendung des proteins s100a 12 als marker für kolorektalkarzinom
ATE520026T1 (de) Sequenzielle analyse biologischer proben
ATE541054T1 (de) Bio-barcode erkennung für zielmoleküle
WO2009076485A3 (en) Sequencing of nucleic acids
BRPI0610092B8 (pt) métodos para a detecção de um analito e de um ácido nucleico em uma amostra, e de sintetização de uma molécula de ácido nucleico ou de análogo de ácido nucleico, kit reagente, uso do mesmo, molécula de ácido nucleico ou de análogo de ácido nucleico e produto associado
ATE462803T1 (de) Kit und verfahren zum nachweis von urothelkarzinom
EP2177614A3 (de) Zusammensetzung und Verfahren zur Diagnose von Speiseröhrenkrebs sowie der Metastasierung von Speiseröhrenkrebs
EP2013561A4 (de) Binäre sonden für fluoreszenzanalyse von nukleinsäuren
ATE520979T1 (de) Biomarker und verfahren zur bestimmung der empfindlichkeit gegenüber modulatoren des egf(epidermal growth factor)-rezeptors
DE602005014386D1 (de) Verwendung von cyfra 21-1 und osteopontin als marker für kolorektalkarzinome
ATE468535T1 (de) Verwendung von nnmt als marker für lungenkrebs
PE20120592A1 (es) Metodo con biomarcadores para el seguimiento de un tratamiento
ATE503846T1 (de) Verfahren zur diagnose eines ovarialkarzinoms
DE602004017317D1 (de) Verwendung der proteine proteinase 3 (prn3) und leukozyten elastatse inhibitor (ileu) als marker für kolorektale karzinome
ATE383418T1 (de) Verfahren und zusammensetzungen zur bestimmung glycierter proteine
WO2009019366A3 (fr) Procede de dosage de l'aminoacylase 1 pour le diagnostic in vitro du cancer colorectal
ATE353544T1 (de) Verwendung des proteins masp als marker für kolorektale karzinome
ATE534037T1 (de) Verwendung des proteins asc als marker für brustkrebs
ATE426168T1 (de) Verwendung von asc als marker fur kolorektalkarzinome
FR2894675B1 (fr) Distinction des meningites bacteriennes et virales
ATE359516T1 (de) Verwendung des proteins crabp ii (cellular retinoic acid-binding protein ii) als marker für brustkrebs

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties